Explosive Growth in India's Pain Relief Market

India's pain relieving market is experiencing unprecedented growth, with over-the-counter (OTC) pills, sprays, and creams becoming increasingly popular for everyday aches and pains. According to Nielsen data, the segment has grown by more than a billion dollars in the past five years, making it the largest category within the non-prescription space.

The Surge of New Brands

Since the pandemic began, an average of five new pain relief brands have been launched each week, increasing the total number from 1,552 in 2020 to 2,771 today. Household names like Volini, Omnigel, Dolo, and Saridon dominate the market.

Consumer Trends and Health Warnings

Consumers are prioritizing quick relief, driven by urbanization and the rise in chronic illnesses. However, healthcare professionals continue to warn about the risks of indiscriminate painkiller use.

From Chronic Pain to Lifestyle Ailments

Pain medications are now being used to treat a wider range of issues, including inflammation, with paracetamol remaining the dominant contributor. Experts link this trend to rising lifestyle-related ailments such as lack of exercise and increased body weight.

The Rise of Self-Medication

Self-medication is on the rise, with serious consequences like kidney damage possible from prolonged use. Top-selling drugs include IPCA’s Zerodol SP and Cipla’s Ibugesic Plus, many of which are prescription medications.

Beyond Pain Relief: Dermatological Products on the Rise

The demand for dermatological creams is also surging, particularly among Gen Z consumers, making derma products the second-largest non-prescription category after pain relief.